Memantine Mylan

Memantine Hydrochloride, the active ingredient in Memantine Mylan, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients and may help improve cognitive function and daily living activities.

GNH USA supplies Memantine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable delivery and compliance with local regulatory requirements throughout.

Memantine Mylan is employed in the therapeutic approach to neurodegenerative disorders characterized by excessive activation of NMDA receptors, which leads to neuronal injury. Its principal and approved clinical use is in Alzheimer’s disease, where it may help maintain cognitive function and daily activities.

Alzheimer’s disease: improves cognition and functional abilities in patients with moderate to severe disease.

Memantine Mylan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness. - Insomnia: difficulty falling or staying asleep. - Confusion: transient disorientation.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Hallucinations: visual or auditory perceptual disturbances. - Cardiac arrhythmia: irregular heart rhythm. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Elevated liver enzymes: indicating possible hepatic stress. - Suicidal thoughts: emergence of depressive ideation.

When prescribing Memantine Mylan, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: adjust dose or monitor renal function. - Hepatic impairment: use with caution and monitor liver tests. - History of seizures: assess risk and observe for seizure activity. - Elderly patients: start at low dose and monitor for confusion. - Concomitant NMDA antagonists: avoid combined use due to additive effects. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Memantine Mylan can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive CNS depression and dissociative effects. - Dextromethorphan: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of renal dysfunction. - Anticholinergic agents: may reduce cognitive benefits of memantine.